Phase I clinical study of 2-(dimethylamino)-3',4'-dihydroxyacetophenone, hydrochloride (NSC-62512).
D000098:Acetophenones / Q000008:administration & dosage* / Q000009:adverse effects; D000818:Animals; D004285:Dogs; D000882:Haplorhini; D006801:Humans; D007275:Injections, Intravenous; D009369:Neoplasms / Q000188:drug therapy*; D051381:Rats
D000098:Acetophenones